Orforglipron Phase 2 trial (NCT05051579)
A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities
At a glance
- Phase
- Phase 2
- Status
- Completed
- Enrolment
- 272
- actual
- Start
- 29 Sep 2021 (actual)
- Primary completion
- 25 Aug 2022 (actual)
- Sponsor
- Eli Lilly and Company
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| 12 milligram (mg) LY3502970 | Experimental | Drug: LY3502970 | Participants received maintenance dose 12 mg with dose escalation starting from 3 mg,6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks. |
| 24 mg LY3502970 | Experimental | Drug: LY3502970 | Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks. |
| 36 mg-1 LY3502970 | Experimental | Drug: LY3502970 | Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks. |
| 36 mg-2 LY3502970 | Experimental | Drug: LY3502970 | Participants received maintenance dose 36 mg with dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks. |
| 45 mg-1 LY3502970 | Experimental | Drug: LY3502970 | Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks. |
| 45 mg-2 LY3502970 | Experimental | Drug: LY3502970 | Participants received maintenance dose 45 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks. |
| Placebo | Placebo comparator | Drug: Placebo | Participants received placebo administered orally once daily until 36 weeks. |
Primary endpoint
| Measure | Time frame |
|---|---|
| Percent Change From Baseline in Body Weight in LY3502970 and Placebo | Baseline, Week 26 |
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Percent Change From Baseline in Body Weight in LY3502970 and Placebo | Baseline, Week 36 |
| Change From Baseline in Body Weight in LY3502970 and Placebo | Baseline, Week 26 |
| Change From Baseline in Body Weight in LY3502970 and Placebo | Baseline, Week 36 |
| Change From Baseline in Waist Circumference in LY3502970 and Placebo | Baseline, Week 26 |
| Change From Baseline in Waist Circumference in LY3502970 and Placebo | Baseline, Week 36 |
| Change From Baseline in BMI in LY3502970 and Placebo | Baseline, Week 26 |
| Change From Baseline in BMI in LY3502970 and Placebo | Baseline, Week 36 |
| Percentage of Participants With >=5% Body Weight Loss | Week 26 |
| Percentage of Participants With >=10% Body Weight Loss | Week 26 |
| Percentage of Participants With >=5% Body Weight Loss | Week 36 |
| Percentage of Participants With >=10% Body Weight Loss | Week 36 |
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Results
Results are posted on the registry. Open the ClinicalTrials.gov record for NCT05051579.
Daily oral orforglipron in adults with obesity, 36-week trial
Participants were randomised to orforglipron at 12, 24, 36 or 45 mg or to placebo once daily for 36 weeks.[2]
At week 26 the mean body weight change ranged from -8.6% to -12.6% across orforglipron groups and was -2.0% with placebo.[2]
At week 36 the range was -9.4% to -14.7% against -2.3% with placebo.[2]
A weight reduction of at least 10% by week 36 occurred in 46 to 75% of orforglipron recipients and 9% of placebo recipients.[2]
Gastrointestinal events led to discontinuation of orforglipron in 10 to 17% of participants across dose cohorts.[2]
Sources
- 1A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related ComorbiditiesClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
- 2Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.The New England journal of medicine · 2023PMID 37351564Accessed 2 Oct 2026
Found an error? Report a correction.